Mary Mackenzie MD, FRCPC
" The only way to improve cancer treatment is through well‑designed clinical trials"
What motivates me is advances in our knowledge of cancer and its treatment that are brought about by clinical trials..... clinical trials are the only way that cancer treatment can improve.
I want to build an investigational new drug treatment program here, so that our patients will have access to cutting‑edge treatments
Dr. Mackenzie completed her MD and FRCPC in Internal Medicine at Dalhousie University in Halifax in 1998. She completed Medical Oncology training and a fellowship in Investigational New Drugs at McMaster University in 2004. Presently she is an Assistant Professor in Medical Oncology, with research interests in phase II trials of investigational new drugs, particularly in renal and gastrointestinal cancers. Tumour types seen include colorectal, gastric, pancreatic, renal and prostate. Dr. Mackenzie is on GI and GU disease site teams and on the clinical research unit committee.
2006 Shim K, Mackenzie MJ, Winquist E. Drug‑Induced Osteonecrosis in Cancer Patients: Incidence, Prevention and Management Drug Therapy in press
2005 Mackay H, Hedley D, Major P, Townsley C, MacKenzie M et al. A Phase II Trial with Pharmacodynamic Endpoints of the Proteasome Inhibitor Bortezomib in Patients with Metastatic Colorectal Cancer. Clin Canc Res. 2005; 11(15):5526‑33.
2005 Hotte SJ, Winquist E, Lamont E, MacKenzie MJ et al. Imatinib Mesylate in patients with c‑kit expressing adenoid cystic cancers of the salivary glands: A Princess Margaret Hospital Phase II Consortium study. J Clin Oncol 2005; 23:585‑590
2005 MacKenzie MJ, Hirte HW, Goss G et al. Phase II trial of ZD1839 (IressaÔ) 750mg per day, an oral epidermal growth factor receptor‑tyrosine kinase inhibitor, in patients with metastatic colorectal cancer. Invest New Drugs 2005; 23:165‑170.
2004 MacKenzie MJ. Molecular therapy in pancreatic adenocarcinoma: current status and future directions. Lancet Oncol. 2004; 5:541‑549.
2004 MacKenzie MJ, Hirte HW, Siu LL et al. A phase I study of OSI‑211 and cisplatin as intravenous infusions given on days 1, 2, and 3 every 3 weeks in patients with solid cancers. Ann Oncol 2004; 15(4):665‑70.
2003 MacKenzie MJ, Major PP. “Mechanisms of Bisphosphonates” Chapter in Cancer Metastasis: Biology and Treatment, Kluwer Academic Publishers, 2003.